针对PGAM5驱动的线粒体综合应激反应减缓了亚型中ALS进展的速度
Zhilong Zheng1, Wangju Yang1, Zhen Chen1
1Department of Neurobiology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing 211166, Jiangsu, China.
Neuron
|March 12, 2026
概括
糖酸突变酶-5 (PGAM5) 被确定为肌缩性侧面硬化症 (ALS) 发病的关键驱动因素,激活线粒体综合应激反应. 抑制PGAM5显示出作为治疗策略的希望,用于各种ALS亚型.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 肌缩性侧面硬化症 (ALS) 呈现出显著的遗传和临床异质性,使其潜在的致病机制的理解变得复杂.
- 调解ALS病变的融合分子途径仍然定义不佳,阻碍了广泛的治疗方法的开发.
研究的目的:
- 为了确定常见的分子媒介的肌缩性侧面硬化症 (ALS) 病原体.
- 研究糖酸突变酶-5 (PGAM5) 在ALS中的作用及其作为治疗点的潜力.
主要方法:
- 利用CRISPR-Cas9查来识别ALS发病过程中的关键蛋白质.
- 研究了PGAM5和金属酶OMA1之间的相互作用,包括酸化部位.
- 在患者样本,有机体和动物模型中评估了PGAM5水平.
- 使用选择性抑制剂 (TAT-PO1) 和药理学剂 (特尔米沙坦) 调节PGAM5活性.
主要成果:
- 糖酸突变酶-5 (PGAM5) 被确定为ALS发病的常见媒介.
- PGAM5通过去化OMA1激活线粒体综合应激反应 (mtISR),从而导致神经肌肉连接中断和运动缺陷.
- 在零星ALS患者,ALS器官和ALS小鼠模型中,PGAM5水平升高.
- 抑制PGAM5-OMA1相互作用或PGAM5本身抑制了mtISR激活,改善了ALS表型.
结论:
- PGAM5在肌缩侧面硬化症 (ALS) 中起到融合和可操作的治疗标作用.
- 针对PGAM5提供了一种潜在的策略,通过调节线粒体综合应激反应来解决ALS的各种亚型.
相关概念视频
02:59Animal Mitochondrial Genetics
Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...
01:46Electron Transport Chain: Complex I and II
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...